You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

pyrotinib

Showing 1 - 25 of 55
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer

Not yet recruiting
  • HER2-positive Breast Cancer
  • Pyrotinib
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Sep 28, 2022

NSCLC Trial in Beijing (Pyrotinib)

Recruiting
  • Non-small Cell Lung Cancer
  • Pyrotinib
  • Beijing, Beijing, China
    Peking Union Medical College
Feb 20, 2023

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line

Recruiting
  • Breast Neoplasms
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Mar 16, 2023

HER2-positive Breast Cancer Trial in Shenyang (SHR-A1811, Pyrotinib)

Not yet recruiting
  • HER2-positive Breast Cancer
  • Shenyang, Liaoning, China
    Shengjing Hospital affiliated to China Medical University
Dec 1, 2022

Advanced Breast Cancer Trial (pyrotinib)

Not yet recruiting
  • Advanced Breast Cancer
  • pyrotinib
  • (no location specified)
Feb 16, 2022

Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in

Recruiting
  • Breast Cancer
  • Pyrotinib
  • Zhejiang, Hangzhou, China
    China
Feb 13, 2022

NSCLC Trial in Shanghai (RC48-ADC, Pyrotinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Feb 16, 2023

Metastatic Breast Cancer Trial in Zhengzhou (Pyrotinib, SHR6390)

Active, not recruiting
  • Metastatic Breast Cancer
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Mar 7, 2022

Breast Cancer Trial in Shenyang (Pyrotinib, Trastuzumab, Dalpiciclib)

Not yet recruiting
  • Breast Cancer
  • Pyrotinib
  • +7 more
  • Shenyang, Liaoning, China
    Shengjing Hospital of China Medical University
Dec 2, 2022

Breast Cancer Invasive Trial in Shanghai (Pyrotinib, Trastuzumab, Pertuzumab)

Active, not recruiting
  • Breast Cancer Invasive
  • Pyrotinib
  • +7 more
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Mar 28, 2022

Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer Trial in Shanghai (Palbociclib, trastuzumab, pyrotinib)

Recruiting
  • Estrogen Receptor-positive Breast Cancer
  • HER2-positive Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Hospital
Sep 29, 2021

Gastric Tumors, Gastroesophageal Junction Adenocarcinoma Trial in Shanghai (Camrelizumab, Pyrotinib, Capecitabine)

Not yet recruiting
  • Gastric Neoplasms
  • Gastroesophageal Junction Adenocarcinoma
  • Shanghai, China
    270 Dongan Road, Fudan University Shanghai Cancer Center
Oct 27, 2021

HER2-positive Breast Cancer Trial in Xi'an (Pyrotinib)

Recruiting
  • HER2-positive Breast Cancer
  • Pyrotinib
  • Xi'an, Shaanxi, China
    Jin Yang
Jun 18, 2022

Colorectal Cancer Trial in Hangzhou (Pyrotinib, Pyrotinib in combination with trastuzumab)

Recruiting
  • Colorectal Cancer
  • Pyrotinib
  • Pyrotinib in combination with trastuzumab
  • Hangzhou, Zhejiang, China
    The Second Affiliated hospital of Zhejiang University School of
Jul 13, 2021

Breast Cancer Trial in Shanghai (Letrozole, Pyrotinib, Dalpiciclib(SHR6390))

Recruiting
  • Breast Cancer
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Jan 21, 2022

Metastatic Breast Cancer Trial (Pyrotinib, Vinorelbine, Inetetamab)

Not yet recruiting
  • Metastatic Breast Cancer
  • Pyrotinib
  • +2 more
  • (no location specified)
Jul 11, 2021

Lapatinib Resistant HER2-Positive Metastatic Breast Cancer

Active, not recruiting
  • Breast Cancer
  • Pyrotinib
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
May 19, 2021

Breast Cancer Trial in Shanghai (Pyrotinib, Placebo)

Active, not recruiting
  • Breast Cancer
  • Pyrotinib
  • Placebo
  • Shanghai, China
    Fudan University Cancer Hospital
May 20, 2021

Breast Cancer Trial in Nanjing (Pyrotinib, Trastuzumab, Pertuzumab)

Recruiting
  • Breast Cancer
  • Pyrotinib
  • +5 more
  • Nanjing, Jiangsu, China
    the First Affiliated Hospital of Nanjing Medical University
Jun 2, 2021

Breast Cancer Trial in Shenyang (Pyrotinib, Trastuzumab)

Not yet recruiting
  • Breast Cancer
  • Shenyang, Liaoning, China
    Shengjing Hospital affiliated to China Medical University
Jul 13, 2021

18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

Completed
  • HER2-positive Breast Cancer
  • Pyrotinib
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 12, 2021

Breast Cancer, Hormone-receptor Positive Breast Cancer Trial in Guangzhou (Pyrotinib, Epirubicin, Doxorubicin Hydrochloride

Recruiting
  • Breast Cancer
  • Hormone-receptor Positive Breast Cancer
  • Pyrotinib
  • +6 more
  • Guangzhou, Guangdong, China
    Sun-Yat-Sen Memorial Hospital of Sun-Yat-Sen University
Apr 29, 2021

Breast Cancer Trial in Guangzhou (Inetetamab, Pyrotinib, Capecitabine)

Recruiting
  • Breast Cancer
  • Guangzhou, Guangdong, China
    Sun Yat Sen Memorial Hospital，Sun Yat sen University
Dec 18, 2020

Metastatic Breast Cancer Trial in Zhengzhou (SHR-A1811, Pyrotinib, Bevacizumab)

Not yet recruiting
  • Metastatic Breast Cancer
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Mar 13, 2023

Metastatic Breast Cancer Trial in Shanghai (Trastuzumab, pyrotinib, Dalpiciclib)

Not yet recruiting
  • Metastatic Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Oct 11, 2022